Article Text

Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome
  1. V V Kaushik,
  2. H V Reddy,
  3. R C Bucknall
  1. Department of Rheumatology, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, UK
  1. Correspondence to:
    Dr V V Kaushik

Statistics from

Churg-Strauss syndrome (CSS) is a disorder characterised by hypereosinophilia and systemic vasculitis occurring in people with asthma and allergic rhinitis. Corticosteroids in combination with a cytotoxic agent are the most effective treatment for CSS. Rituximab, a genetically engineered chimeric anti-CD20 monoclonal antibody has recently been tried with favourable responses in chronic immunological diseases.1 Several published reports have shown its effectiveness in ANCA mediated vasculitides.2,3 We present a patient with CSS who responded well to rituximab after conventional treatments had failed.

A 49 year old, white male patient with a long history of asthma presented in 2000 with inflammatory polyarthritis, bilateral scleritis, and negative autoantibodies. He was managed as a patient with seronegative …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.